FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Mama a														
Name and Address of Reporting Person* Young Richard A			2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 04/15/2020					-	Office	er (give title belo	ow)	Other (specify b	pelow)	
(Street) CAMBRIDGE, MA 02140				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				
	(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)		Г	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any	, if (3. Transac Code (Instr. 8)	(A) c	4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		Beneficia Reported	ant of Securities ally Owned Following I Transaction(s)		Ownership Form:	Beneficial
				(Month/Day/Ye	ear)	Code	V Amount (A) or (D) Pri		Price			Ownership (Instr. 4)		
Commor	Stock	O	04/15/2020			S ⁽¹⁾	23,9	60 D	\$ 8.75	371,141			D	
							y or indired Persons v	ho respor	nd to t	he collec	ction of inf	formation	SEC	1474 (9-02)
				Derivative Secu	rities	s Acquire	Persons vecontained the form of	who respor in this for lisplays a d	m are curren eficiall	not requ ntly valid	uired to res	spond unle	ss	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Ye	3A. Deemed Execution Date any	Derivative Secures, puts, calls, 4. Transaction Code (Instr. 8)	strities warr 5. Nu of De See Ac (A Di of (In	s Acquire	Persons vecontained the form of	who responding this for lisplays and of, or Bendertible security ercisable tion Date	eficiall rities) 7. Tit Amo Unde	not required to the second of	OMB con 8. Price of	spond unle	of 10. Owners Form of Security Direct (or Indire	11. Natu of Indire Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Young Richard A C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140	X				

Signatures

/s/ Gerald E. Quirk, as attorney-in-fact	04/17/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.